Drug Profile
Atrial natriuretic factor prohormone 31-67 - Madeleine Pharmaceuticals
Alternative Names: MAD-001; MP-3167; Pro ANP 31-67; ProANF 31-67; Vastiras; Vessel dilator - Madeleine; VSDLLatest Information Update: 17 Aug 2018
Price :
$50
*
At a glance
- Originator Madeleine Pharmaceuticals
- Developer Madeleine Pharmaceuticals; Medtronic
- Class Heart failure therapies; Natriuretic peptides; Peptides
- Mechanism of Action Atrial natriuretic factor receptor agonists; Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Heart failure
Most Recent Events
- 30 Jul 2018 Madeleine terminates the phase II CONTINUUM-HF trial for Heart failure in Australia (IV, infusion; SC, infusion) (ACTRN12613001060730)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in Australia (SC, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in Australia (SC, Implant)